Roth MKM Reaffirms Their Buy Rating on Allurion Technologies (ALUR)
In a report released today, Jason Wittes from Roth MKM maintained a Buy rating on Allurion Technologies (ALUR – Research Report), with a price ...
Allurion Technologies price target lowered to $16 on split-adjusted basis
Roth MKM lowered the firm’s price target on Allurion Technologies (ALUR) to $16 from $50 and keeps a Buy rating on the shares. The firm is ...
Yahoo Finance22d
Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline
NATICK, Mass., February 19, 2025--(BUSINESS WIRE)--Allurion Technologies, Inc. ("Allurion" or the "Company") (NYSE: ALUR), a company dedicated to ending obesity ...
Roth Capital Has Pessimistic Outlook of ALUR Q1 Earnings
Research analysts at Roth Capital dropped their Q1 2025 EPS estimates for Allurion Technologies in a research note issued to investors on Wednesday, March 5th. Roth Capital analyst J. Wittes now ...
Morningstar8d
Allurion Announces Notification of Issuance of New U.S. Patents on Next-Generation Weight Loss Device for the Treatment of Obesity
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has received two Issue Notifications from the U.S ...
Business Wire22d
Allurion Announces Plans To Combine GLP-1 Therapy With The Allurion Balloon to Treat Obesity
NATICK, Mass.--(BUSINESS WIRE)--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced ...
Business Wire15d
Allurion to Participate in Upcoming Investor Conferences
Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it will be partici ...
Yahoo Finance27d
Allurion Relaunches in France
Company considering sites in France for clinical trial on combination therapy of Allurion Balloon and GLP-1s to prevent muscle loss NATICK, Mass., February 13, 2025--(BUSINESS WIRE)--Allurion ...
Nasdaq21d
Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline
NATICK, Mass.--(BUSINESS WIRE)-- Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered into a ...
Nasdaq27d
Allurion Relaunches in France
ANSM, the French regulatory authority, clears Allurion to resume sales of the Allurion Balloon Company considering sites in France for clinical trial on combination therapy of Allurion Balloon and ...
Morningstar21d
Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline
Allurion to Raise Approximately $6.1 Million of Gross Proceeds in Offering and Concurrent Private Placement to Advance GLP-1 Clinical Pipeline Allurion Technologies, Inc. (“Allurion” or the ...